Ovid Therapeutics (OVID) Intangibles (2016 - 2022)

Ovid Therapeutics has reported Intangibles for 7 years, with the latest figure at $244000.0 in Q1 2022.

• For the quarter ending Q1 2022, Intangibles fell 7.22% year-over-year to $244000.0; the trailing twelve-month figure through Mar 2022 stood at $244000.0 (down 7.22% YoY), and the FY2021 full-year result was $263000.0, down 17.55% from the prior year.
• Intangibles for Q1 2022 stood at $244000.0, down from $263000.0 in the prior quarter.
• The five-year high for Intangibles was $467000.0 in Q4 2019, with the low at $160390.0 in Q1 2018.
• Historically, Intangibles has averaged $316341.2 across 5 years, with a median of $319000.0 in 2020.
• Annual changes were most pronounced in 2018 — Intangibles soared 234.71% — and 2021, when it sank 45.43%.
• Ovid Therapeutics' Intangibles stood at $392000.0 in 2018, then increased by 19.13% to $467000.0 in 2019, then plunged by 31.69% to $319000.0 in 2020, then declined by 17.55% to $263000.0 in 2021, then decreased by 7.22% to $244000.0 in 2022.
• The last three Intangibles figures came in at $244000.0 (Q1 2022), $263000.0 (Q4 2021), and $197000.0 (Q3 2021), per Business Quant data.